Literature DB >> 12464783

99mTc-MIBI and 201Tl SPET in the detection of recurrent brain tumours after radiation therapy.

Y Yamamoto1, Y Nishiyama, Y Toyama, K Kunishio, K Satoh, M Ohkawa.   

Abstract

The purpose of this study was to evaluate whether Tc-hexakis-2-methoxyisobutylisonitrile ( Tc-MIBI) or Tl single photon emission tomography (SPET) could detect recurrent tumours in patients with previous radiation therapy for brain tumours. Dual SPET with Tc-MIBI and Tl was performed in 21 patients suspected of having recurrent brain tumours. SPET images were acquired 15 min (early) and 2 h (delayed) after injection. The ratio of the average counts for the region of interest in the lesion area and its mirror image in normal brain tissue was obtained. Early and delayed ratios were calculated. On the basis of histological and/or clinical findings, the final diagnosis was considered as recurrent tumours in 15 patients and radiation necrosis in six. Both ratios using Tc-MIBI and Tl were significantly higher in recurrent tumours than in radiation necrosis. Based on a cut-off of 5.89 of the early ratio using Tc-MIBI to distinguish between recurrent tumours and radiation necrosis, the accuracy was 90%. Based on a cut-off of 6.77 of the delayed ratio using Tc-MIBI, the accuracy was 86%. The corresponding values using cut-offs of 2.40 and 1.85 with Tl were 90% and 86%, respectively. However, within recurrent tumours, both ratios for Tc-MIBI were significantly higher than those for Tl. Early Tc-MIBI SPET may be especially useful for the detection of recurrent tumours in patients who have previously undergone radiation therapy for brain tumours.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12464783     DOI: 10.1097/00006231-200212000-00006

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  7 in total

1.  99mTc-Tetrofosmin SPECT for the detection of glioma recurrence.

Authors:  George A Alexiou; Spyridon Tsiouris; Athanasios P Kyritsis; Konstantinos S Polyzoidis; Andreas D Fotopoulos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-20       Impact factor: 9.236

Review 2.  Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies.

Authors:  Nishant Verma; Matthew C Cowperthwaite; Mark G Burnett; Mia K Markey
Journal:  Neuro Oncol       Date:  2013-01-16       Impact factor: 12.300

3.  Thallium-201 SPECT: the optimal prediction of response in glioma therapy.

Authors:  Maaike J Vos; Johannes Berkhof; Tjeerd J Postma; Otto S Hoekstra; Frederik Barkhof; Jan J Heimans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-29       Impact factor: 9.236

Review 4.  Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape.

Authors:  Benjamin M Ellingson; Caroline Chung; Whitney B Pope; Jerrold L Boxerman; Timothy J Kaufmann
Journal:  J Neurooncol       Date:  2017-04-05       Impact factor: 4.130

Review 5.  Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities.

Authors:  George A Alexiou; Spyridon Tsiouris; Athanasios P Kyritsis; Spyridon Voulgaris; Maria I Argyropoulou; Andreas D Fotopoulos
Journal:  J Neurooncol       Date:  2009-04-21       Impact factor: 4.130

Review 6.  The role of SPET and PET in monitoring tumour response to therapy.

Authors:  Chariklia Giannopoulou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-14       Impact factor: 9.236

7.  Radiological diagnosis of brain radiation necrosis after cranial irradiation for brain tumor: a systematic review.

Authors:  Motomasa Furuse; Naosuke Nonoguchi; Kei Yamada; Tohru Shiga; Jean-Damien Combes; Naokado Ikeda; Shinji Kawabata; Toshihiko Kuroiwa; Shin-Ichi Miyatake
Journal:  Radiat Oncol       Date:  2019-02-06       Impact factor: 3.481

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.